Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-speciWc T-cell-mediated antitumor immune response

Cancer Immunology, Immunotherapy

Volumn 60, Issue 9, 2011, Pages 1289-1297

  Takahara, Akitaka ^a   Koido, Shigeo ^a   Ito, Masaki ^a   Nagasaki, Eijiro ^a   Sagawa, Yukiko ^a   Iwamoto, Takeo ^a   Komita, Hideo ^a   Ochi, Toshiki ^b   Fujiwara, Hiroshi ^b   Yasukawa, Masaki ^b   Mineno, Junichi ^c   Shiku, Hiroshi ^d   Nishida, Sumiyuki ^e   Sugiyama, Haruo ^e   Tajiri, Hisao ^a   Homma, Sadamu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TAKARA BIO INC   (Japan)

^d MIE UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gemcitabine; NF kappa B; Pancreatic cancer; T cell response; WT1

Indexed keywords

ASPARAGINE; CYSTEINE; GEMCITABINE; GLUTAMINE; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUCINE; MESSENGER RNA; METHIONINE; PROTEASOME; THREONINE; TRYPTOPHAN; WT1 PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL NUCLEUS; CELL SPECIFICITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOREGULATION; MASS SPECTROMETRY; MOUSE; NONHUMAN; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PROCESSING; SCID MOUSE; T LYMPHOCYTE RECEPTOR GENE; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIMETABOLITES, ANTINEOPLASTIC; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; DEOXYCYTIDINE; GENE EXPRESSION; GENES, T-CELL RECEPTOR; HLA-A24 ANTIGEN; HUMANS; MICE; MICE, SCID; PANCREATIC NEOPLASMS; RNA, MESSENGER; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; UP-REGULATION; WT1 PROTEINS;

EID: 80054691705     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1033-3     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96 (Pubitemid 351521864)
2. Heinemann V (2002) Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 29(6 Suppl20):9-16 (Pubitemid 36207367)
3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10-30 (Pubitemid 40310185)
4. Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B, Gallinger S (2004) Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198:722-731 (Pubitemid 38542900)
5. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567-579
6. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347-353 (Pubitemid 26246785)
7. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413 (Pubitemid 27251144)
8. Li J, Merl MY, Chabot J, Saif MW (2010) Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the "2010 ASCO annual meeting". Chicago, IL, USA. June 4-8. J Pancreas 11: 310-312
9. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
10. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré- Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto- Grillot C, Ducreux M, Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825
11. Coppes MJ, Campbell CE, Williams BR (1993) The role of WT1 in Wilms tumorigenesis. FASEB J 7:886-895 (Pubitemid 23225545)
12. Rauscher FJ 3rd (1993) The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J 7:896-903 (Pubitemid 23225546)
13. Haber DA, Park S, Maheswaran S, Englert C, Re GG, Hazen-Martin DJ, Sens DA, Garvin AJ (1993) WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science 262(5142):2057-2059 (Pubitemid 24041889)
14. Hutchings Y, Osada T, Woo CY, Clay TM, Lyerly HK, Morse MA (2007) Immunotherapeutic targeting of Wilms' tumor protein. Curr Opin Mol Ther 9:62-69 (Pubitemid 46438450)
15. Sugiyama H (2005) Cancer immunotherapy targeting Wilms' tumor gene WT1 product. Expert Rev Vaccines 4:503-512 (Pubitemid 41297297)
16. Gaiger A, Carter L, Greinix H, Carter D, McNeill PD, Houghton RL, Cornellison CD, Vedvick TS, Skeiky YA, Cheever MA (2001) WT1-specific serum antibodies in patients with leukemia. Clin Cancer Res 7(3 Suppl):761s-765s (Pubitemid 33600924)
17. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323-5337
18. Oji Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, Tatsumi N, Abeno S, Ikeba A, Takashima S, Tsujie M, Yamamoto H, Sakon M, Nezu R, Kawano K, Nishida S, Ikegame K, Kawakami M, Tsuboi A, Oka Y, Yoshikawa K, Aozasa K, Monden M, Sugiyama H (2004) Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci 95:583-587 (Pubitemid 39089639)
19. Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M, Nakamura Y, Yamaue H (2010) Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 101:433-439
20. Yanagimoto H, Mine T, Yamamoto K, Satoi S, Terakawa N, Takahashi K, Nakahara K, Honma S, Tanaka M, Mizoguchi J, Yamada A, Oka M, Kamiyama Y, Itoh K, Takai S (2007) Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 98:605-611 (Pubitemid 46562753)
21. Sipos B, Möser S, Kalthoff H, Török V, Löhr M, Klöppel G (2003) A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 442:444-452 (Pubitemid 36718311)
22. Storkus WJ, Zeh HJ 3rd, Maeurer MJ, Salter RD, Lotze MT (1993) Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol 151:3719-3727 (Pubitemid 23282684)
23. Ohminami H, Yasukawa M, Fujita S (2000) HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95:286-293 (Pubitemid 30017254)
24. Okamoto S, Mineno J, Ikeda H, Fujiwara H, Yasukawa M, Shiku H, Kato I (2009) Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res 69:9003-9011
25. Yasukawa M, Ohminami H, Arai J, Kasahara Y, Ishida Y, Fujita S (2000) Granule exocytosis, and not the fas/fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4(+) as well as CD8(+) cytotoxic T lymphocytes in humans. Blood 95:2352-2355 (Pubitemid 30167735)
26. Bottero V, Busuttil V, Loubat A, Magné N, Fischel JL, Milano G, Peyron JF (2001) Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res 61:7785-7791 (Pubitemid 33049365)
27. Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse ML, Fölsch UR, Schäfer H (2003) Role of NF-kappaB and Akt/PI3 K in the resistance of pancreatic carcinoma cell lines against gemcitabineinduced cell death. Oncogene 22:3243-3251 (Pubitemid 36712936)
28. Dehbi M, Hiscott J, Pelletier J (1998) Activation of the wt1 Wilms' tumor suppressor gene by NF-kappaB. Oncogene 16:2033-2039 (Pubitemid 28211678)
29. Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CD (2008) Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res 14:8143-8151
30. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67:3853-3861 (Pubitemid 46762173)
31. Banerjee S, Wang Z, Kong D, Sarkar FH (2009) 3, 3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 69:5592-5600
32. Vajjhala PR, Macmillan E, Gonda T, Little M (2003) The Wilms' tumour suppressor protein, WT1, undergoes CRM1-independent nucleocytoplasmic shuttling. FEBS Lett 554(1-2):143-148 (Pubitemid 37324829)
33. Silberstein GB, Van Horn K, Strickland P, Roberts CT Jr, Daniel CW (1997) Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA 94:8132-8137 (Pubitemid 27343789)
34. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H, Aozasa K (2006) Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 19:804-814 (Pubitemid 43780450)
35. Ye Y, Raychaudhuri B, Gurney A, Campbell CE, Williams BR (1996) Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation. EMBO J 15:5606-5615 (Pubitemid 26385620)
36. Sijts A, Zaiss D, Kloetzel PM (2001) The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design. Curr Mol Med 1:665-676 (Pubitemid 33772942)
37. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM (2005) Gemcitabine selectively eliminates splenic Gr-1 +/ CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11:6713-6721 (Pubitemid 41339014)
38. Plate JM, Plate AE, Shott S, Bograd S, Harris JE (2005) Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54:915-925 (Pubitemid 40991334)